NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $98.9K invested in NeuroSense Therapeutics Warrant in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.
441% more capital invested
Capital invested by funds: $18.3K → $98.9K (+$80.6K)
33% more funds holding
Funds holding: 3 → 4 (+1)
0.22% more ownership
Funds ownership: 1.78% → 2% (+0.22%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$5.56K |
| 2 |
CS
Clear Street
New York
|
-$25 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $36.4K | – | – | – |
|
|
CS
2
Clear Street
New York
| $24.9K | -$25 | -100 | -0.2% |
|
|
3
Citadel Advisors
Miami,
Florida
| $20.2K | +$12.1K | +48,138 | New |
|
|
WAM
4
Warberg Asset Management
Winnetka,
Illinois
| $17.4K | -$5.56K | -22,096 | -35% |
|
NRSNW Hedge Fund Activity: Q1 2024 in Review
4 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q1 2024, worth a combined $98.9K — up 441% from $18.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $12.1K. The largest seller was Warberg Asset Management, cutting an estimated $5.56K.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q1 2024, up from 3 in Q4 2023.
- Funds reported $98.9K of NeuroSense Therapeutics Warrant stock for Q1 2024, up 441% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics Warrant buyer in Q1 2024 was Citadel Advisors, an estimated $12.1K added.
- The largest NeuroSense Therapeutics Warrant seller in Q1 2024 was Warberg Asset Management, an estimated $5.56K sold.
Based on aggregated 13F filings for Q1 2024.